RSMDF Quote, Financials, Valuation and Earnings

VolitionRX Ltd. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of -862.39%. ResMed, Inc.'s return on equity of 25.6% beat VolitionRX Ltd.'s return on equity of --.

ResMed, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 779.04%. Given that VolitionRX Ltd. has higher upside potential than ResMed, Inc., analysts believe VolitionRX Ltd. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.775, which suggesting that the stock is 22.482% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

ResMed, Inc. has a quarterly dividend of $0.06 per share corresponding to a yield of 0.83%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.14% of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. ResMed, Inc.'s net income of $348.5M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, ResMed, Inc.'s price-to-earnings ratio is 27.89x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.63x versus 19.49x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of -1037.17%. ResMed, Inc.'s return on equity of 25.6% beat Catheter Precision, Inc.'s return on equity of -192.05%.

ResMed, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1496.69%. Given that Catheter Precision, Inc. has higher upside potential than ResMed, Inc., analysts believe Catheter Precision, Inc. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.775, which suggesting that the stock is 22.482% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

ResMed, Inc. has a quarterly dividend of $0.06 per share corresponding to a yield of 0.83%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.14% of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. ResMed, Inc.'s net income of $348.5M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, ResMed, Inc.'s price-to-earnings ratio is 27.89x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.63x versus 11.19x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 3.93%. ResMed, Inc.'s return on equity of 25.6% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

ResMed, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 150.92%. Given that Xtant Medical Holdings, Inc. has higher upside potential than ResMed, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.775, which suggesting that the stock is 22.482% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

ResMed, Inc. has a quarterly dividend of $0.06 per share corresponding to a yield of 0.83%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.14% of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. ResMed, Inc.'s net income of $348.5M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, ResMed, Inc.'s price-to-earnings ratio is 27.89x while Xtant Medical Holdings, Inc.'s PE ratio is 58.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.63x versus 0.65x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.